Roberta Arb Saba

Roberta Arb Saba

Auto-generated profile, based on publicly available information

Roberta Arb Saba

Federal University of São Paulo, Department of Neurology and Neurosurgery, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
RSRoberta Arb Saba
Roberta Arb Saba
DMDébora Palma Maia
Débora Palma Maia
FCFrancisco Eduardo Costa Cardoso
Francisco Eduardo Costa Cardoso
VBVanderci Borges
Vanderci Borges
LALuiz Augusto F. Andrade
Luiz Augusto F. Andrade
MCMarcus Vinicius Della Colletta
Marcus Vinicius Della Colletta
The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best evidence to the Brazilian reality. Thus, the main published treatment guidelines were reviewed based on the recommendations of group from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology.

1 July 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
CGClecio Godeiro
Clecio Godeiro
Carina FrançaCarina França
Carina França
RCRafael Bernhart Carra
Rafael Bernhart Carra
FSFelipe Saba
Felipe Saba
RSRoberta Saba
Roberta Saba
RCRubens Gisbert Cury
Rubens Gisbert Cury
Background: Noninvasive stimulation has been widely used in the past 30 years to study and treat a large number of neurological diseases, including movement disorders. Objective: In this critical review, we illustrate the rationale for use of these techniques in movement disorders and summarize the best medical evidence based on the main clinical trials performed to date. Methods: A nationally representative group of experts performed a comprehensive review of the literature in order to analyze the key clinical decision-making factors driving transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) in movement disorders. Classes of evidence and recommendations were described for each disease. Results: Despite unavoidable heterogeneities and low effect size, TMS is likely to be effective for treating motor symptoms and depression in Parkinson’s disease (PD). The efficacy in other movement disorders is unclear. TMS is possibly effective for focal hand dystonia, essential tremor and cerebellar ataxia. Additionally, it is likely to be ineffective in reducing tics in Tourette syndrome. Lastly, tDCS is likely to be effective in improving gait in PD. Conclusions: There is encouraging evidence for the use of noninvasive stimulation on a subset of symptoms in selected movement disorders, although the means to optimize protocols for improving positive outcomes in routine clinical practice remain undetermined. Similarly, the best stimulation paradigms and responder profile need to be investigated in large clinical trials with established therapeutic and assessment paradigms that could also allow genuine long-term benefits to be determined.

1 April 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
SBSonia Maria Dozzi Brucki
Sonia Maria Dozzi Brucki
TATarso Adoni
Tarso Adoni
CACarlos Mauricio O MAURICIO OLIVEIRA de Almeida
Carlos Mauricio O MAURICIO OLIVEIRA de Almeida
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
RARenato Anghinah
Renato Anghinah
GPGilmar Fernandes do Prado
Gilmar Fernandes do Prado
Cannabinoids comprehend endocannabinoids, phytocannabinoids, and synthetic cannabinoids, with actions both in the central and peripherical nervous systems. A considerable amount of publications have been made in recent years, although cannabis has been known for over a thousand years. Scientific Departments from the Brazilian Academy of Neurology described evidence for medical use in their areas. Literature is constantly changing, and possible new evidence can emerge in the next days or months. Prescription of these substances must be discussed with patients and their families, with knowledge about adverse events and their efficacy.

1 February 2020 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
RCRaphael Machado Castilhos
Raphael Machado Castilhos
MAMarina Coutinho Augustin
Marina Coutinho Augustin
JSJosé Augusto dos Santos
José Augusto dos Santos
JPJosé Luiz Pedroso
José Luiz Pedroso
OBOrlando G. P. Barsottini
Orlando G. P. Barsottini
RNRede Neurogenética
Rede Neurogenética
Carnitine is a metabolite derived from amino acids and plays a critical role in energy production, transporting long-chain fatty acids into the mitochondria, and toxic compounds out of this organelle3. Decline in mitochondrial function has been associated with aging, as well as with HD4. Carnitine concentration declines with age, reducing the integrity of the mitochondrial membrane3; this effect might be potentiated in HD5. Although carnitine does not participate directly on the energy resources used by the central nervous system (CNS), early findings related deficits of this metabolite to HD. Cuturic et al. reported low serum levels of carnitine in 26% (6/23) institutionalized HD patients5.

15 January 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
DMDébora Palma Maia
Débora Palma Maia
RCRubens Gisbert Cury
Rubens Gisbert Cury
Pedro Renato de Paula BrandãoPedro Renato de Paula Brandão
Pedro Renato de Paula Brandão
FCFrancisco E. C. Cardoso
Francisco E. C. Cardoso
ABAna Paula Bertholo
Ana Paula Bertholo
RSRoberta Arb Saba
Roberta Arb Saba
The treatment of Parkinson's disease (PD) is a challenge, especially because it is considered highly individualized. The Brazilian Academy of Neurology (ABN) has identified the need to disseminate knowledge about its management, adapting the best evidence to the Brazilian population. The present article aims to report the recommendations for the treatment of non-motor symptoms of PD, developed by a group of specialists in movement disorders from the ABN's scientific department. In 2021, the first part, referring to the motor symptoms of PD, was published. The main non-motor symptoms were addressed—among them neuropsychiatric symptoms, such as depression, anxiety, cognitive alteration, and psychosis—as well as the possible recommended therapies and medications used to control pain, sleep disorders, and dysautonomia.

3 September 2025 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
DBDayany Leonel Boone
Dayany Leonel Boone
VTVitor Tumas
Vitor Tumas
GVGabriel Vilela
Gabriel Vilela
VBVanderci Borges
Vanderci Borges
RPRoberta Arb Saba Rodrigues Pinto
Roberta Arb Saba Rodrigues Pinto
HFHenrique B. Ferraz
Henrique B. Ferraz